close
References
  1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533.
  2. Mahungu TW, Rodger AJ, Johnson MA. HIV as a chronic disease. Clin Med (Lond). 2009;9(2):125-128.
  3. Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs, and the promise of the future. Br J Clin Pharmacol. 2015;79(2):182-194.
  4. United States Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
    https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/
    AdultandAdolescentGL.pdf    . Updated December 18, 2019. Accessed September 10, 2020.
  5. National Institutes of Health. 10 things to know about HIV suppression. www.niaid.nih.gov/diseases-conditions/10-things-know-about-hiv-suppression. Updated June 12, 2020. Accessed September 10, 2020.
  6. Centers for Disease Control and Prevention. HIV treatment and care. www.cdc.gov/hiv/clinicians/treatment/treatment-clinicians.html. Updated August 17, 2020. Accessed September 10, 2020.
  7. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on National HIV surveillance data from 25 states, United States. J Acquir Immune Def Syndr. 2010;53(1):124-130.
  8. Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349-e356.
  9. Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open. 2020;3(6):e207954.
  10. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
  11. Siddiqi AE, Hall HI, Hu X, Song R. Population-based estimates of life expectancy after HIV diagnosis: United States 2008-2011. J Acquir Immune Defic Syndr. 2016;72(2):230-236.
  12. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256-266.
  13. Earnshaw VA, Bogar LM, Dovidio JF, Williams DR. Stigma and racial/ethnic HIV disparities: moving toward resilience. Am Psychol. 2013;68(4):225-236.
  14. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18(2):226-240.
  15. Essuon AD, Zhao H, Wang G, Collins N, Karch D, Rao S. HIV testing outcomes among Blacks or African Americans — 50 local U.S. jurisdictions accounting for the majority of new HIV diagnoses and seven states with disproportionate occurrences of HIV in rural areas, 2017. MMWR Morb Mortal Wkly Rep. 2020;69(4):97-102.
  16. Radix A, Shalev N, Medical Care Criteria Committee. New York State Department of Health AIDS Institute. When to initiate antiretroviral therapy, with protocol for rapid initiation. www.hivguidelines.org/antiretroviral-therapy/when-to-start-plus-rapid-start/#tab_3. Updated January 2020. Accessed September 10, 2020.
  17. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  18. Riddell J 4th. 2018 IAS-USA recommendations for the use of antiretroviral therapy for HIV: building on decades of progress. JAMA. 2018;320(4):347-349.
  19. Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(5):e1002015.
  20. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel. JAMA. 2018;320(4):379-396.
  21. Hall HI, Tang T, Johnson AS, Espinoza L, Harris N, McCray E. Timing of linkage to care after HIV diagnosis and time to viral suppression. J Acquir Immune Defic Syndr. 2016;72(2):e57-e60.
  22. National Institutes of Health’s Office of Aids Research. Following an HIV regimen: steps to take before and after starting HIV medicines. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/following-hiv-regimen-steps-take-and-after-starting-hiv-medicines. Updated September 16, 2020. Accessed September 20, 2020.
  23. Centers for Disease Control and Prevention. ART adherence. www.cdc.gov/hiv/clinicians/treatment/art-adherence.html. Updated October 21, 2019. Accessed September 10, 2020.
  24. Infectious Diseases Society of America. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. www.idsociety.org/practice-guideline/prevention-and-treatment-of-opportunistic-infections-among-adults-and-adolescents. Updated May 29, 2018. Accessed September 10, 2020.
  25. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297-1307.
  26. Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care. 2013;19(12 Suppl):s231-s237.
  27. Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640.
  28. Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. Fed Pract. 2016;33(Suppl 3):24s-30s.
  29. Centers for Disease Control and Prevention. What is HIV treatment? www.cdc.gov/hiv/basics/livingwithhiv/treatment.html. Updated October 17, 2019. Accessed September 10, 2020.  
  30. National Institutes of Health’s Office of Aids Research. HIV treatment adherence. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets. Updated January 15, 2020. Accessed September 10, 2020.
  31. Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med. 2014;371(3):248-259.
  32. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.
  33. Centers for Disease Control and Prevention. Compendium of evidence-based interventions and best practices for HIV prevention. www.cdc.gov/hiv/research/interventionresearch/compendium/index.html. Updated August 17, 2020. Accessed September 10, 2020.
  34. Centers for Disease Control and Prevention. HIV effective interventions: treat. www.cdc.gov/hiv/effective-interventions/treat/index.html. Updated June 27, 2020. Accessed September 10, 2020.